Adam Feuerstein and Jonathan Wosen

BioTech

Sanofi advances a drug for a rare, platelet-destroying disease

(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.) Greetings

Adam Feuerstein and Jonathan Wosen December 7, 2024

BioTech

Vertex non-opioid drug reduces chronic nerve pain in mid-stage study

Vertex Pharmaceuticals said Wednesday that an experimental drug reduced pain in people with diabetes who have chronic nerve pain — mid-stage study results that support

Adam Feuerstein and Jonathan Wosen December 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Adam Feuerstein and Jonathan Wosen

Sanofi advances a drug for a rare, platelet-destroying disease

Vertex non-opioid drug reduces chronic nerve pain in mid-stage study

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe